{"DataElement":{"publicId":"4716663","version":"1","preferredName":"Breast Carcinoma Disease Response Current Status","preferredDefinition":"Text descriptor of the state of breast carcinoma in an individual.","longName":"BRST_CA_RESP_STAT","context":"LCC","contextVersion":"1","DataElementConcept":{"publicId":"4716656","version":"1","preferredName":"Breast Carcinoma Disease Response Current Evaluation","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females_The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression._Occurring in or belonging to the present time._Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria._","longName":"4716654v1.0:3853621v1.0","context":"LCC","contextVersion":"1","ObjectClass":{"publicId":"4716654","version":"1","preferredName":"Breast Carcinoma Disease Response","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.:The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","longName":"C4872:C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0ED6B2EF-23A8-6C6D-E050-BB89AD4369A6","latestVersionIndicator":"Yes","beginDate":"2015-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-02-11","modifiedBy":"ONEDATA","dateModified":"2015-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3853621","version":"1","preferredName":"Current Evaluation","preferredDefinition":"Occurring in or belonging to the present time.:Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"C25471:C25214","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Current","conceptCode":"C25471","definition":"Occurring in or belonging to the present time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Evaluation","conceptCode":"C25214","definition":"Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3CBFDC0-2B34-5845-E040-BB89AD435489","latestVersionIndicator":"Yes","beginDate":"2013-08-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-12","modifiedBy":"ONEDATA","dateModified":"2013-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0ED6B2EF-23B6-6C6D-E050-BB89AD4369A6","latestVersionIndicator":"Yes","beginDate":"2015-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-02-11","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for CRF Harmonization per request by Response WG. mc 8/12/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4716658","version":"1","preferredName":"Breast Carcinoma Disease Response Status","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females._The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression._A condition or state at a particular time.","longName":"BRST_CA_RESP_ST","context":"LCC","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"40","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Distant recurrence","valueDescription":"Distant Recurrent Breast Carcinoma","ValueMeaning":{"publicId":"4716659","version":"1","preferredName":"Distant Recurrent Breast Carcinoma","longName":"4716659","preferredDefinition":"A biological process that involves the transfer and growth of cancer cells from the site of the primary tumor. Relocation of malignant cells during metastasis can be restricted to movement within a specific tissue/organ or may entail migration to a distal locus within the body. This phenotype is a characteristic of all malignant tumors.: The return of a disease after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Distant Metastasis","conceptCode":"C18206","definition":"A biological process that involves the transfer and growth of cancer cells from the site of the primary tumor. Relocation of malignant cells during metastasis can be restricted to movement within a specific tissue/organ or may entail migration to a distal locus within the body. This phenotype is a characteristic of all malignant tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0ED6DA95-285D-1DE8-E050-BB89AD430F00","latestVersionIndicator":"Yes","beginDate":"2015-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0ED6DA95-2876-1DE8-E050-BB89AD430F00","beginDate":"2015-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-02-11","modifiedBy":"ONEDATA","dateModified":"2015-02-11","deletedIndicator":"No"},{"value":"Regional recurrence","valueDescription":"Regional Recurrent Disease","ValueMeaning":{"publicId":"4716660","version":"1","preferredName":"Regional Recurrent Disease","longName":"4716660","preferredDefinition":"Limited to a particular location or area.: The return of a disease after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Regional","conceptCode":"C25643","definition":"Of or belonging to a broader area or region of the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0ED6DA95-2883-1DE8-E050-BB89AD430F00","latestVersionIndicator":"Yes","beginDate":"2015-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0ED6DA95-289C-1DE8-E050-BB89AD430F00","beginDate":"2015-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-02-11","modifiedBy":"ONEDATA","dateModified":"2015-02-11","deletedIndicator":"No"},{"value":"Contralateral breast recurrence","valueDescription":"Contralateral Recurrent Breast Carcinoma","ValueMeaning":{"publicId":"4716661","version":"1","preferredName":"Contralateral Recurrent Breast Carcinoma","longName":"4716661","preferredDefinition":"On or relating to the opposite side (of the body): A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.: The return of a disease after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Contralateral","conceptCode":"C25307","definition":"On or relating to the opposite side of the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0ED6DA95-28AA-1DE8-E050-BB89AD430F00","latestVersionIndicator":"Yes","beginDate":"2015-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0ED6DA95-28C3-1DE8-E050-BB89AD430F00","beginDate":"2015-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-02-11","modifiedBy":"ONEDATA","dateModified":"2015-02-11","deletedIndicator":"No"},{"value":"Ipsilateral breast recurrence","valueDescription":"Ipsilateral Recurrent Breast Carcinoma","ValueMeaning":{"publicId":"4716662","version":"1","preferredName":"Ipsilateral Recurrent Breast Carcinoma","longName":"4716662","preferredDefinition":"Having to do with the same side of the body.: A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.: The return of a disease after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipsilateral","conceptCode":"C25308","definition":"Having to do with the same side of the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0ED6DA95-28D1-1DE8-E050-BB89AD430F00","latestVersionIndicator":"Yes","beginDate":"2015-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0ED6DA95-28EA-1DE8-E050-BB89AD430F00","beginDate":"2015-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-02-11","modifiedBy":"ONEDATA","dateModified":"2015-02-11","deletedIndicator":"No"},{"value":"No Evidence of Disease (NED)","valueDescription":"No Evidence of Disease","ValueMeaning":{"publicId":"2559523","version":"1","preferredName":"No Evidence of Disease","longName":"2559523","preferredDefinition":"Diagnostic tests fail to detect presence of disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No Evidence of Disease","conceptCode":"C40413","definition":"Diagnostic tests fail to detect presence of disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B590-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0ED6DA95-28F4-1DE8-E050-BB89AD430F00","beginDate":"2013-08-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-02-11","modifiedBy":"ONEDATA","dateModified":"2015-02-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"4716657","version":"1","preferredName":"Breast Carcinoma Disease Response Status","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.:The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.:A condition or state at a particular time.","longName":"C4872:C50995:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0ED6DA95-2837-1DE8-E050-BB89AD430F00","latestVersionIndicator":"Yes","beginDate":"2015-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-02-11","modifiedBy":"ONEDATA","dateModified":"2015-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0ED6DA95-2848-1DE8-E050-BB89AD430F00","latestVersionIndicator":"Yes","beginDate":"2015-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-02-11","modifiedBy":"REEVESD","dateModified":"2015-02-11","changeDescription":"Created for CRF Harmonization per request by Response WG. mc 8/14/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2812571","version":"1","longName":"Lombardi Cancer Center","context":"NCIP"},{"publicId":"2812605","version":"1","longName":"Lombardi New CDEs","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Disease status","type":"Preferred Question Text","description":"Disease status","url":null,"context":"LCC"}],"origin":"C3D:Central Cancer Clinical Database","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"0ED6B2EF-23DF-6C6D-E050-BB89AD4369A6","latestVersionIndicator":"Yes","beginDate":"2015-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-02-11","modifiedBy":"REEVESD","dateModified":"2015-04-14","changeDescription":"Curated to support Lombardi Cancer Center clinical trial","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}